SalusPharma announces the close of a multi-million-yuan Series A

Isiah Liu

SalusPharma announced that it has completed a Series A financing round, raising tens of millions of yuan. The round was co-invested by Kaitai Capital and Zhongnan Capital.

SalusPharma was established in the United States in December 2010. The company specializes in the development and innovation of pharmaceutical processes and drug delivery technologies to develop and manufacture derivative new drugs and innovative drugs.

The company uses its unique osmotic pump sustained release technology and pellet controlled release expertise to develop NDA and ANDA drugs. The core founding team has more than 20 years of work experience in pharmaceutical R&D, process development, drug production, and drug registration.

At present, the company's product pipeline is centered on osmotic pump technology-based sustained and controlled release preparations. It has established a unique osmotic pump and pellet controlled release technology platform. SalusPharma has more than 10 products in development, mainly covering the treatment ofchronic diseases such as hypertension, diabetes and others.


Xbed Xi Hotel receives RMB100 million in financing
Tourism , PEVC

Memoray completes tens of millions of yuan in Series B financing
PEVC , Medical care

JD Health and AstraZeneca start strategic cooperation
Medical care , Pharmaceutical

Sier Education closes multi-mln-dollar Pre-A led by Qiming Venture Partners
Education , PEVC

Eugenlight Technologies closes Series A of RMB tens of millions
PEVC , Semiconductor , Electroinic

ABM Therapeutics closes USD20m Series A+ round led by China Growth Capital
PEVC , Pharmaceutical , Therapeutic

Lupeng Pharmaceutical closes RMB170m Series A+ round led by Lilly Asia Ventures
Pharmaceutical , PEVC

Small-molecule innovative drug developer Lynk Pharma secures multi-million-dollar Series A
Pharmaceuticals , PEVC , Medical care

Atom Bioscience completes RMB150m in Series B financing
Biotech , PEVC , Pharmaceutical
China SDG